{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:37:19Z","timestamp":1740109039543,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00345-021-03714-5","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T07:02:54Z","timestamp":1621407774000},"page":"4135-4142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Can serum endoglin be used to improve the diagnostic performance in prostate cancer?"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3523-1661","authenticated-orcid":false,"given":"Francisco","family":"Pina","sequence":"first","affiliation":[]},{"given":"Ana","family":"Ferro","sequence":"additional","affiliation":[]},{"given":"Francisco","family":"Botelho","sequence":"additional","affiliation":[]},{"given":"Margarida","family":"Manso","sequence":"additional","affiliation":[]},{"given":"Nuno","family":"Dias","sequence":"additional","affiliation":[]},{"given":"Gabriela","family":"Figueiredo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8465-7330","authenticated-orcid":false,"given":"Pedro","family":"Pereira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2893-5492","authenticated-orcid":false,"given":"Paulo","family":"Dinis","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4699-6571","authenticated-orcid":false,"given":"Henrique","family":"Barros","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1870-1430","authenticated-orcid":false,"given":"Nuno","family":"Lunet","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"key":"3714_CR1","first-page":"2896","volume-title":"Campbell-Walsh UROLOGY","author":"M Gretzer","year":"2007","unstructured":"Gretzer M, Partin AW (2007) Prostate Cancer Tumor Markers. In: Kavoussi LR et al (eds) Campbell-Walsh UROLOGY. Library of Congress Cataloging-in-Publication Data, Philadelphia, pp 2896\u20132911"},{"issue":"1","key":"3714_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/gerona\/gls135","volume":"68","author":"BT Howrey","year":"2013","unstructured":"Howrey BT et al (2013) The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States. J Gerontol A Biol Sci Med Sci 68(1):56\u201361","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"6","key":"3714_CR3","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.eururo.2013.01.011","volume":"63","author":"M Lazzeri","year":"2013","unstructured":"Lazzeri M et al (2013) Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2\u201310 ng\/ml: a multicentric European study. Eur Urol 63(6):986\u2013994","journal-title":"Eur Urol"},{"issue":"3","key":"3714_CR4","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.eururo.2015.04.028","volume":"69","author":"K Braun","year":"2016","unstructured":"Braun K et al (2016) A four-kallikrein panel predicts high-grade cancer on biopsy: independent validation in a community cohort. Eur Urol 69(3):505\u2013511","journal-title":"Eur Urol"},{"issue":"1","key":"3714_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.eururo.2014.08.010","volume":"68","author":"T Nordstr\u00f6m","year":"2015","unstructured":"Nordstr\u00f6m T et al (2015) Comparison between the four-kallikrein panel and prostate health index for predicting prostate cancer. Eur Urol 68(1):139\u2013146","journal-title":"Eur Urol"},{"issue":"3","key":"3714_CR6","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.24007","volume":"124","author":"K Fujita","year":"2009","unstructured":"Fujita K et al (2009) Endoglin (CD105) as a urinary and serum marker of prostate cancer. Int J Cancer 124(3):664\u2013669","journal-title":"Int J Cancer"},{"key":"3714_CR7","doi-asserted-by":"crossref","unstructured":"Keith B. and M.C. Simon, Tumor Angiogenesis, in The Molecular Basis of Cancer, J. Mendelsohn, et al., Editors. 2008, W. B. Saunders Company: Philadelphia, USA.","DOI":"10.1016\/B978-141603703-3.10018-4"},{"issue":"10","key":"3714_CR8","first-page":"1005","volume":"49","author":"BK Seon","year":"2001","unstructured":"Seon BK et al (2001) Angiogenesis and netastasis marker of human tumors. Rinsho Byori 49(10):1005\u20131013","journal-title":"Rinsho Byori"},{"issue":"54","key":"3714_CR9","doi-asserted-by":"publisher","first-page":"8272","DOI":"10.1038\/sj.onc.1206117","volume":"21","author":"Y Liu","year":"2002","unstructured":"Liu Y et al (2002) Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion. Oncogene 21(54):8272\u20138281","journal-title":"Oncogene"},{"issue":"12","key":"3714_CR10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/j.1440-1827.2006.02037.x","volume":"56","author":"R Minhajat","year":"2006","unstructured":"Minhajat R et al (2006) Organ-specific endoglin (CD105) expression in the angiogenesis of human cancers. Pathol Int 56(12):717\u2013723","journal-title":"Pathol Int"},{"issue":"10","key":"3714_CR11","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.1158\/0008-5472.CAN-10-2665","volume":"71","author":"D Romero","year":"2011","unstructured":"Romero D et al (2011) Endoglin regulates cancer-stromal cell interactions in prostate tumors. Cancer Res 71(10):3482\u20133493","journal-title":"Cancer Res"},{"issue":"1","key":"3714_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10585-010-9356-6","volume":"28","author":"M Lakshman","year":"2011","unstructured":"Lakshman M et al (2011) Endoglin suppresses human prostate cancer metastasis. Clin Exp Metastasis 28(1):39\u201353","journal-title":"Clin Exp Metastasis"},{"issue":"9","key":"3714_CR13","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/iju.12840","volume":"22","author":"Y Miyata","year":"2015","unstructured":"Miyata Y, Sakai H (2015) Reconsideration of the clinical and histopathological significance of angiogenesis in prostate cancer: Usefulness and limitations of microvessel density measurement. Int J Urol 22(9):806\u2013815","journal-title":"Int J Urol"},{"issue":"1","key":"3714_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12253-010-9287-1","volume":"17","author":"U Agrawal","year":"2011","unstructured":"Agrawal U et al (2011) Role of tumor suppressor and angiogenesis markers in prediction of recurrence of non muscle invasive bladder cancer. Pathol Oncol Res 17(1):91\u2013101","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"3714_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s10120-006-0401-8","volume":"10","author":"NI Nikiteas","year":"2007","unstructured":"Nikiteas NI et al (2007) Vascular endothelial growth factor and endoglin (CD-105) in gastric cancer. Gastric Cancer 10(1):12\u201317","journal-title":"Gastric Cancer"},{"issue":"4","key":"3714_CR16","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1309\/X6NXYE57DLUE2NQ8","volume":"127","author":"YM El-Gohary","year":"2007","unstructured":"El-Gohary YM et al (2007) Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am J Clin Pathol 127(4):572\u2013579","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"3714_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3109\/00365599.2012.669791","volume":"46","author":"A Josefsson","year":"2012","unstructured":"Josefsson A et al (2012) Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance. Scand J Urol Nephrol 46(4):247\u2013257","journal-title":"Scand J Urol Nephrol"},{"issue":"10","key":"3714_CR18","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/j.bbalip.2012.12.005","volume":"1831","author":"CJ Fowler","year":"2013","unstructured":"Fowler CJ et al (2013) Tumour epithelial expression levels of endocannabinoid markers modulate the value of endoglin-positive vascular density as a prognostic marker in prostate cancer. Biochim Biophys Acta 1831(10):1579\u20131587","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"3714_CR19","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/j.1464-410X.2006.06006.x","volume":"97","author":"J Sandlund","year":"2006","unstructured":"Sandlund J et al (2006) Endoglin (CD105) expression in human renal cell carcinoma. BJU Int 97(4):706\u2013710","journal-title":"BJU Int"},{"issue":"1","key":"3714_CR20","first-page":"39","volume":"37","author":"Y Yao","year":"2007","unstructured":"Yao Y et al (2007) Endoglin (CD105) expression in angiogenesis of primary hepatocellular carcinomas: analysis using tissue microarrays and comparisons with CD34 and VEGF. Ann Clin Lab Sci 37(1):39\u201348","journal-title":"Ann Clin Lab Sci"},{"issue":"2","key":"3714_CR21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/sj.pcan.4500716","volume":"7","author":"W Kassouf","year":"2004","unstructured":"Kassouf W et al (2004) Whole-mount prostate sections reveal differential endoglin expression in stromal, epithelial, and endothelial cells with the development of prostate cancer. Prostate Cancer Prostatic Dis 7(2):105\u2013110","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"3714_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/ERC-19-0370","volume":"27","author":"VR Placencio-Hickok","year":"2020","unstructured":"Placencio-Hickok VR et al (2020) Soluble CD105 is prognostic of disease recurrence in prostate cancer patients. Endocr Relat Cancer 27(1):1\u20139","journal-title":"Endocr Relat Cancer"},{"key":"3714_CR23","doi-asserted-by":"publisher","first-page":"25776","DOI":"10.1038\/srep25776","volume":"6","author":"Y Cui","year":"2016","unstructured":"Cui Y et al (2016) Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis. Sci Rep 6:25776","journal-title":"Sci Rep"},{"key":"3714_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1741-7015-6-19","volume":"6","author":"AJ Vickers","year":"2008","unstructured":"Vickers AJ et al (2008) A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European randomized study of prostate cancer screening in G\u00f6teborg, Sweden. BMC Med 6:19","journal-title":"BMC Med"},{"issue":"15","key":"3714_CR25","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2009.24.1968","volume":"28","author":"A Vickers","year":"2010","unstructured":"Vickers A et al (2010) Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol 28(15):2493\u20132498","journal-title":"J Clin Oncol"},{"issue":"2","key":"3714_CR26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000064844","volume":"65","author":"A Manseck","year":"2000","unstructured":"Manseck A et al (2000) Is systematic sextant biopsy suitable for the detection of clinically significant prostate cancer? Urol Int 65(2):80\u201383","journal-title":"Urol Int"},{"issue":"3","key":"3714_CR27","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.21873\/anticanres.14088","volume":"40","author":"AC Vidal","year":"2020","unstructured":"Vidal AC et al (2020) Soluble Endoglin (sCD105) as a novel biomarker for detecting aggressive prostate cancer. Anticancer Res 40(3):1459\u20131462","journal-title":"Anticancer Res"},{"issue":"8","key":"3714_CR28","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/pros.20938","volume":"69","author":"RS Svatek","year":"2009","unstructured":"Svatek RS et al (2009) Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate 69(8):886\u2013894","journal-title":"Prostate"},{"issue":"5","key":"3714_CR29","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1158\/1078-0432.CCR-07-0901","volume":"14","author":"JA Karam","year":"2008","unstructured":"Karam JA et al (2008) Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer. Clin Cancer Res 14(5):1418\u20131422","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3714_CR30","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.3109\/0284186X.2013.813070","volume":"52","author":"S Isebaert","year":"2013","unstructured":"Isebaert S et al (2013) Identification and characterization of nodal metastases in prostate cancer patients at high risk for lymph node involvement. Acta Oncol 52(7):1336\u20131344","journal-title":"Acta Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-021-03714-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-021-03714-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-021-03714-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T15:04:14Z","timestamp":1636124654000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-021-03714-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["3714"],"URL":"https:\/\/doi.org\/10.1007\/s00345-021-03714-5","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"type":"print","value":"0724-4983"},{"type":"electronic","value":"1433-8726"}],"subject":[],"published":{"date-parts":[[2021,5,19]]},"assertion":[{"value":"8 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FP has received grants for: participating in the Advisory Board of Darolutamide on Prostate Cancer\/Lisbon 2019-11-29, BAYER PORTUGAL; participating in the Advisory Board on Prostate Cancer\/Lisbon 2020-05-10, Delphi\/IQUVIA; and for being Principal Investigator and National Coordinator of the ARAMIS International Protocol for CRPCnm no. 3,104,007, ORION PHARMA\/BAYER 2014\u20132020. FB has received a speaker honorarium from Astellas and has participated as a consultant for Janssen-Cilag, both unrelated to this study. The remaining authors did not report conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Ethics Committee of the S. Jo\u00e3o Hospital Center (CES 52-14).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Data were collected retrospectively from clinical files and anonymized for analysis. No specific consent was obtained from patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}